Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ

Inclusion Criteria

• •Disease Characteristics
• •The patient must be male or female 18 years of age or older.
• •The patient must have histologically-confirmed Transitional Cell Carcinoma (TCC) of the bladder.
• •The patient must have histologically-confirmed carcinoma in situ (CIS), with or without non-invasive papillary disease
• •The patient must have immunohistochemically-confirmed EpCAM positive disease.
• •The patient must have a life expectancy of at least 12 months.
• •Prior/Concurrent Therapy
• •The patient must have, within the last 24 months, failed to respond to at least 1 cycle of treatment with BCG (with or without interferon) or be intolerant to BCG treatment.
• •The patient must have had a transurethral resection of the bladder tumour (TURBT) mapping the location of tumour and quantifying the area of bladder affected.
• •The patient must have documented residual CIS (i.e. unresectable disease) prior to study drug administration.
• •Patient Characteristics
• •The patient must have adequate organ function, as defined by the clinical trial protocol
• •Other
• •The patient must have the ability to understand and sign an Independent Ethics Committee or Institutional Review Board (IEC/IRB)- approved informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment and is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.